Patent intelligence · US
US 11376214
Compositions and methods for treatment of ocular diseases
Compositions and methods for treatment of ocular diseases
Patent details — US 11376214
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 5, 2022
- Expiration
- Jun 30, 2042
- Applicant
- KIORA PHARMACEUTICALS GmbH
- Claims
- 27
- CPC classes
- A61K, A61K31/4709, A61K31/55, A61K31/7036
Quick answer
US 11376214 (Compositions and methods for treatment of ocular diseases) is held by KIORA PHARMACEUTICALS GmbH. Status: granted. Granted Jul 5, 2022. Expires Jun 30, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- KIORA PHARMACEUTICALS GmbH
- Grant date
- Expiration
- Claims
- 27
- CPC classes
- A61K, A61K31/4709, A61K31/55, A61K31/7036, A61K47/36, A61K9/0048
More from KIORA PHARMACEUTICALS GmbH
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11376214?
US 11376214 (Compositions and methods for treatment of ocular diseases) is held by KIORA PHARMACEUTICALS GmbH. Status: granted. Granted Jul 5, 2022. Expires Jun 30, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11376214?
KIORA PHARMACEUTICALS GmbH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 11376214 expire?
Our index shows an expiration date of Jun 30, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.